Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva Systems (NYSE:VEEV) has announced it will host its 2025 Investor Day virtually on October 16, 2025. The event will run from 1:30 p.m. to 3:30 p.m. PT (4:30 p.m. to 6:30 p.m. ET).
Investors can access the live presentations through Veeva's investor relations website at ir.veeva.com, where an archived version will also be available after the event. Registration for the online event is available through the company's IR website.
Veeva Systems (NYSE:VEEV) announced that Bristol Myers Squibb (BMS) has committed to implementing Veeva Vault CRM, marking a significant expansion of their existing partnership. The collaboration focuses on leveraging AI-powered customer relationship management to enhance healthcare practitioner engagement.
The Vault CRM suite will feature four AI agents - Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent - scheduled for release in December 2025. This technology aims to transform how BMS interacts with healthcare practitioners and streamlines the delivery of information about their medicine portfolio.
Veeva Systems (NYSE:VEEV) announced that Gilead Sciences has committed to implementing Veeva Vault CRM, expanding their existing partnership. The Vault CRM Suite will serve as the foundation for Gilead's commercial execution, featuring advanced AI capabilities including pre-call planning, compliant free text, and voice control functionalities.
This strategic partnership aims to enhance Gilead's commercial operations through Veeva's AI-powered CRM platform, which is designed to improve efficiency and effectiveness in commercial execution. The collaboration represents a significant expansion of the relationship between the two companies, with Gilead's global CIO expressing enthusiasm about exploring Veeva AI's potential.
Veeva Systems (NYSE:VEEV) announced its upcoming participation in Citi's 2025 Global TMT Conference in New York. CFO Brian Van Wagener and EVP Strategy Paul Shawah will deliver a presentation on Thursday, September 4, 2025, at 2:10 p.m. ET.
The presentation will be accessible through a webcast, with both live and archived versions available on Veeva's investor relations website.
Veeva Systems (NYSE:VEEV) announced significant adoption of its Regulatory Information Management (RIM) platform, now used by over 450 companies, including 19 of the top 20 biopharmas. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to enhance multi-health authority platform integration.
The platform's continuous publishing feature through Veeva Submissions Publishing is being utilized by more than 85 organizations to accelerate submission timelines. Accumulus's network connects over 70 regulatory agencies worldwide, while DNAnexus integration aims to improve inter-agency collaboration for faster product approvals.
Veeva Systems (NYSE:VEEV) has announced a strategic collaboration with Amgen to enhance clinical trial innovation. Amgen will implement the Veeva Clinical Platform to optimize their clinical trial processes and accelerate drug development for serious diseases.
The collaboration includes implementation and change management support from Veeva Business Consulting. Amgen's CIO Scott Skellenger highlighted that this partnership aims to unlock new capabilities for end-to-end trial operations, while Veeva Development Cloud President Jim Reilly emphasized the platform's role in speeding up drug delivery through standardized and connected processes.
Veeva Systems (NYSE:VEEV) reported strong fiscal 2026 second quarter results with total revenues of $789.1M, up 17% year-over-year. Subscription services revenues increased 17% to $659.2M. The company achieved notable financial metrics, including non-GAAP operating income of $352.6M (up 26%) and non-GAAP net income of $333.4M (up 25%).
Key developments include the progress of Veeva AI with planned releases starting December, significant Vault CRM Suite milestones with over 100 customers live, and a strategic partnership with IQVIA. The company updated its FY2026 guidance, projecting total revenues between $3,134M and $3,140M.
Veeva Systems (NYSE:VEEV) has announced details for its upcoming R&D and Quality Summit, scheduled for September 3-4 in Boston. The event will bring together over 2,000 life sciences professionals from leading companies including Alnylam, BeOne Medicines, Intercept, Merck, Pfizer, and Sanofi.
A key highlight will be the showcase of Veeva AI, built into the Vault Platform with secure access to data, documents, and workflows. The summit will feature more than 100 sessions focusing on accelerating development, manufacturing processes, and improving trial oversight. Notable case studies include Merck's clinical operations streamlining, FUJIFILM Biotechnologies' global quality management implementation, and Sanofi's study training optimization.
IQVIA (NYSE:IQV) and Veeva Systems (NYSE:VEEV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.
The partnership encompasses two key areas: Commercial collaboration, establishing master data and third-party access agreements for mutual data usage across platforms, and Clinical integration, with IQVIA joining Veeva's CRO Clinical Data Partner program to leverage the Veeva Clinical Suite for clinical trials execution.
The collaboration aims to enhance customer efficiency by streamlining product integration and accelerating clinical development processes, database builds, study locks, and data delivery.
Veeva Systems (NYSE:VEEV) and IQVIA (NYSE:IQV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.
The commercial partnership establishes master data and third-party access agreements, allowing mutual data usage across platforms including Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations.